Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Oct 1;34(10):1765-1766.
doi: 10.1681/ASN.0000000000000206. Epub 2023 Aug 18.

Of End Points and Context of Use: A Reasonable Silver Lining for Urinary Chemokines Monitoring

Angelica Pagliazzi  1 , Elisabet Van Loon  1   2 , Maarten Naesens  1   2
Affiliations
Comment

Of End Points and Context of Use: A Reasonable Silver Lining for Urinary Chemokines Monitoring

Angelica Pagliazzi et al. J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

M. Naesens is involved in a clinical study with CareDx (Brisbane, CA), involving the use of donor-derived cell-free DNA in kidney transplant recipients. M. Naesens also reports Consultancy: Agomab, Aiosyn, Argenx, and Hansa; Research Funding: CareDx; Honoraria: Argenx and Hansa; and Patents or Royalties: M. Naesens is inventor of two patents related to the FWO-SBO application—EP19152365.3: mRNA-based biomarkers for antibody-mediated transplant rejection. This biomarker was licensed in September 2020 to CareDx, a precision medicine solutions company focused on solutions for transplant patients—PCT/EP2018/097044: Biomarkers for typing allograft recipients (patent application submitted in December 2018). E. Van Loon reports Patents or Royalties: Shared inventorship of European patent mRNA-based biomarker for antibody-mediated transplant rejection, filed on January 17, 2019. The remaining author has nothing to disclose.

Comment in

Comment on

References

    1. Hirt-Minkowski P Handschin J Stampf S, et al. . Randomized trial to assess the clinical utility of renal allograft monitoring by urine CXCL10 chemokine. J Am Soc Nephrol. 2023;34(8):1456–1469. doi:10.1681/ASN.0000000000000160 - DOI - PMC - PubMed
    1. Tinel C Devresse A Vermorel A, et al. . Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. Am J Transplant. 2020;20:3462–3476. doi:10.1111/ajt.15959 - DOI - PubMed
    1. Oellerich M Sherwood K Keown P, et al. . Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Nat Rev Nephrol. 2021;17(9):591–603. doi: 10.1038/s41581-021-00428-0 - DOI - PubMed
    1. Becker JU, Seron D, Rabant M, Roufosse C, Naesens M. Evolution of the definition of rejection in kidney transplantation and its use as an endpoint in clinical trials. Transpl Int. 2022;35:10141. doi:10.3389/ti.2022.10141 - DOI - PMC - PubMed

LinkOut - more resources